Beta blockers tied to improved TNBC survival
Author: Shreeya Nanda medwireNews: Among women with triple-negative breast cancer (TNBC), the use of beta blockers may improve BC-specific survival, suggests a population-based cohort study and meta-analysis. “The biological reason behind the association between β-blocker use and improved prognosis for TNBC patients but not for other BC patients remains unclear,” say the study authors in […]
Neutrophil to lymphocyte ratio may help identify ICI candidates in NSCLC
Author: Laura Cowen medwireNews: A low baseline neutrophil to lymphocyte ratio (NLR) may identify patients with non-small-cell lung cancer (NSCLC) who are more likely to derive survival benefit from atezolizumab than from docetaxel, study findings indicate. Writing in Cancer, Alessio Cortellini (Imperial College London, UK) and co-authors say: “The NLR proved to be an effective tool […]
JAVELIN Bladder 100 exploratory analyses point to wide use of maintenance avelumab
Author: Shreeya Nanda medwireNews: Maintenance treatment with avelumab improves the long-term outcomes of advanced urothelial cancer patients regardless of their response to first-line chemotherapy and receipt of second-line therapy, suggest exploratory analyses of the JAVELIN Bladder 100 trial. The findings were presented in posters at the 2022 ASCO Annual Meeting in Chicago, Illinois, USA, and […]
Perioperative immunotherapy for NSCLC: Perspectives from an oncologist and a surgeon
Martin Reck and Hans Hoffmann discuss the optimal clinical trial endpoints and patient selection for neoadjuvant and adjuvant immunotherapy for resectable non-small-cell lung cancer (14:58).
Impower010 trial update confirms adjuvant atezolizumab efficacy for patients with high PD-L1 expression
Nasser Altorki talks through the high PD-L1 expression sub-analysis findings from the IMpower010 trial of adjuvant atezolizumab versus best supportive care for stage II–IIIA NSCLC (5:37).
Neoadjuvant osimertinib shows promise for EGFR-mutated NSCLC
Chao Lyu discusses the final efficacy and safety results from the NEOS trial, demonstrating the benefits of osimertinib for EGFR-mutated resectable stage II–IIIB lung adenocarcinoma in the neoadjuvant setting (4:03).
Olaparib plus abiraterone could be a new first-line treatment option for mCRPC
Fred Saad provides an overview of the PROpel study of olaparib plus abiraterone acetate for the first-line treatment of metastatic castration-resistant prostate cancer, and outlines the next steps (3:41).
PROpel: mCRPC patients benefit from add-on olaparib
Author: Shreeya Nanda medwireNews: Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC), show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA. The presenting author – Fred Saad, from Centre Hospitalier de l’Université de Montréal in Quebec, Canada […]
Darolutamide add-on prolongs survival in mHSPC
Author: Laura Cowen medwireNews: Adding the androgen receptor inhibitor darolutamide to androgen-deprivation therapy plus docetaxel significantly improves overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC), show data from the phase 3 ARASENS trial. Furthermore, the “survival benefit was observed despite a high percentage of patients who received subsequent life-prolonging systemic therapy in […]
ATLANTIS points to maintenance benefit of rucaparib in mUC
Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials (4:47). This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, […]
